Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTEST: Toripalimab and Tifcemalimab with Chemotherapy and LDRT in First-line ES-SCLC
NCT06732258Phase 1Withdrawn
- Sponsor
- Sichuan University
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of toripalimab and tifcemalimab in small cell lung cancer (SCLC), sponsored by Sichuan University. Primary endpoint: Dose-limiting Toxicity at 21 days. Planned start Jan 2025; status: withdrawn.
02
Drugs
toripalimabtifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06732258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732258.